Glycyrrhizin as a potential disease-modifying therapy for epilepsy: insights into targeting pyroptosis to exert neuroprotective and anticonvulsant effects
BackgroundFor patients with epilepsy, antiseizure medication remains the primary treatment; however, it is ineffective in approximately 30% of cases. These patients experience progressive neuronal damage and poor outcomes. Therefore, there is an urgent need for disease-modifying therapy (DMT) that t...
Saved in:
Main Authors: | Lei Wei, Sijie Ou, Youshi Meng, Lanfeng Sun, Lin Zhang, Yuling Lu, Yuan Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1530735/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glycyrrhizinate Monoammonium Cysteine-Loaded Lipid Nanoparticles Allow for Improved Acute Liver Injury Therapy
by: Yunjie Xu, et al.
Published: (2025-01-01) -
Glycyrrhizin attenuates renal inflammation in a mouse Con A-hepatitis model via the IL-25/M2 axis
by: Lingyun Li, et al.
Published: (2024-12-01) -
Ivermectin as a promising therapeutic option for onchocerciasis‐associated epilepsy
by: Mohammad Amin Manavi, et al.
Published: (2025-02-01) -
Microglial C/EBPβ-Fcgr1 regulatory axis blocking inhibits microglial pyroptosis and improves neurological recovery
by: Jing Li, et al.
Published: (2025-01-01) -
Cerebrospinal fluid‐specific oligoclonal bands in dogs with idiopathic epilepsy
by: Junwei Föhr, et al.
Published: (2025-01-01)